Showing 1 - 20 results of 27 for search 'Jos H Beijnen', query time: 0.04s
Refine Results
-
1
Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis by Anke E. Kip, Monique Wasunna, Fabiana Alves, Jan H. M. Schellens, Jan H. M. Schellens, Jos H. Beijnen, Jos H. Beijnen, Jos H. Beijnen, Ahmed M. Musa, Eltahir A. G. Khalil, Thomas P. C. Dorlo
Published 2018-06-01
Article -
2
-
3
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? by Nancy H. C. Loos, Jos H. Beijnen, Alfred H. Schinkel
Published 2022-08-01
Article -
4
-
5
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availabili... by Wenlong Li, Rolf W. Sparidans, Maria C. Lebre, Jos H. Beijnen, Alfred H. Schinkel
Published 2021-10-01
Article -
6
-
7
The G2 checkpoint—a node‐based molecular switch by Mark C. deGooijer, Arnout van denTop, Irena Bockaj, Jos H. Beijnen, Thomas Würdinger, Olaf vanTellingen
Published 2017-04-01
Article -
8
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO) by Yaogeng Wang, Rolf W. Sparidans, Sander Potters, Rahime Şentürk, Maria C. Lebre, Jos H. Beijnen, Alfred H. Schinkel
Published 2021-10-01
Article -
9
-
10
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure by Jing Wang, M. Merve Susam, Changpei Gan, Rolf W. Sparidans, Maria C. Lebre, Jos H. Beijnen, Alfred H. Schinkel
Published 2022-09-01
Article -
11
-
12
-
13
-
14
-
15
-
16
A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients by Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
Published 2023-02-01
Article -
17
-
18
Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c by Nancy H.C. Loos, Irene A. Retmana, Jamie Rijmers, Yaogeng Wang, Changpei Gan, Maria C. Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel
Published 2023-10-01
Article -
19
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling by Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Marcel P. M. Stokkel, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
Published 2023-08-01
Article -
20
Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis by Marlies H.G. Langenberg, Petronella O. Witteveen, Nienke A.G. Lankheet, Jeanine M.L. Roodhart, Hilde Rosing, Ingeborg J.G.M. van den Heuvel, Jos H. Beijnen, Emile E. Voest
Published 2010-02-01
Article